Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04071327 · ClinicalTrials.gov registry record
Pulmonary Hypertension Association Registry
A clinical trial of Pulmonary Hypertension and Pulmonary Arterial Hypertension, sponsored by Pulmonary Hypertension Association.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 20
- Study locations
NCT04071327 is a study of Pulmonary Hypertension and Pulmonary Arterial Hypertension that is actively recruiting participants, run by Pulmonary Hypertension Association. The registered enrollment target is 3,000 participants, above the 572-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (424% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT04071327, a study of Pulmonary Hypertension and Pulmonary Arterial Hypertension, is actively recruiting participants, sponsored by Pulmonary Hypertension Association.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH are treated according to recommended guidelines, and to see if there are certain factors that can lead to better or worse outcomes. PHAR will include information about people with PAH and CTEPH in the U.S. who are seen at participating PHA-accredited PH Care Centers. PHAR contains data about patient care and outcomes. Specifically, data in the PHAR includes information on diagnosis; clinical status; socioeconomic status; diagnosis test results; body size; treatment information; interest in participating in clinical trials; family health and social history; and information about smoking, alcohol, or drug use. Participants are followed over time, and provide updates such as changes in therapy, how often participants need to go to the hospital, and survival. Such information may help healthcare providers provide better care.
Conditions Studied
Study Locations (20)
California
- UC Davis Health - Sacramento
- UCSF Medical Center - San Francisco
- UCSF Benioff Children's Hospital - San Francisco
- Cottage Health System - Santa Barbara Pulmonary Associates - Santa Barbara
- Stanford University - Stanford
Colorado
- Children's Hospital Colorado - Aurora
- UC Health - Anschutz Medical Campus - Aurora
Louisiana
- Ochsner Medical Center - Jefferson
- LSU Healthcare Network Clinic - New Orleans
Maryland
- University of MD Medical Group, PA - Baltimore
- Johns Hopkins University - Baltimore
Arizona
- Arizona Pulmonary Specialists, Ltd. - Phoenix
Connecticut
- University of Connecticut Health - Farmington
Florida
- Mayo Clinic Florida - Jacksonville
Georgia
- Northside Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2015-10 |
| Est. Completion | 2025-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04071327
The ClinicalTrials.gov registry entry for NCT04071327 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 572-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (424% higher). The listed sponsor is Pulmonary Hypertension Association, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 0 interventions.
NCT04071327 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Colorado, Louisiana.
Frequently Asked Questions
What is clinical trial NCT04071327 about?
NCT04071327 is a clinical study titled "Pulmonary Hypertension Association Registry". The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Ce...
What is the current status of trial NCT04071327?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2015-10. Estimated completion is 2025-12.
What conditions does trial NCT04071327 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension.
Who is sponsoring clinical trial NCT04071327?
This trial is sponsored by Pulmonary Hypertension Association, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04071327 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
RECRUITING
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders
RECRUITING
-
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
RECRUITING · Phase 3
-
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.